148 related articles for article (PubMed ID: 32183944)
1. Context-Dependent Immune Responses Explain Pancreatic Cancer Immunoresistance.
Bednar F; Pasca di Magliano M
Cancer Cell; 2020 Mar; 37(3):261-263. PubMed ID: 32183944
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
Anagnostou VK; Brahmer JR
Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
[TBL] [Abstract][Full Text] [Related]
3. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.
Kakimi K; Nakajima J; Wada H
Lung Cancer; 2009 Jul; 65(1):1-8. PubMed ID: 19062127
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
[TBL] [Abstract][Full Text] [Related]
5. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
7. "RIPping" off Pancreas Cancer's Blockage of Immune Surveillance.
Liu X; Sells BE; DeNardo DG
Cancer Discov; 2024 Feb; 14(2):208-210. PubMed ID: 38327192
[TBL] [Abstract][Full Text] [Related]
8. New Immunotherapy and Lung Cancer.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell vaccines against non-small cell lung cancer - an emerging therapeutic alternative.
Mendoza L
Klin Onkol; 2014; 27(4):294-8. PubMed ID: 25115721
[TBL] [Abstract][Full Text] [Related]
10. [Vaccines for the treatment of non-small cell lung cancer].
Leduc C; Quoix E
Rev Mal Respir; 2019 Mar; 36(3):415-425. PubMed ID: 30902445
[TBL] [Abstract][Full Text] [Related]
11. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
Papachristofilou A; Hipp MM; Klinkhardt U; Früh M; Sebastian M; Weiss C; Pless M; Cathomas R; Hilbe W; Pall G; Wehler T; Alt J; Bischoff H; Geißler M; Griesinger F; Kallen KJ; Fotin-Mleczek M; Schröder A; Scheel B; Muth A; Seibel T; Stosnach C; Doener F; Hong HS; Koch SD; Gnad-Vogt U; Zippelius A
J Immunother Cancer; 2019 Feb; 7(1):38. PubMed ID: 30736848
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination.
Van den Heuvel MM; Burgers SA; van Zandwijk N
Clin Lung Cancer; 2009 Mar; 10(2):99-105. PubMed ID: 19362952
[TBL] [Abstract][Full Text] [Related]
13. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.
Carbone DP; Gandara DR; Antonia SJ; Zielinski C; Paz-Ares L
J Thorac Oncol; 2015 Jul; 10(7):974-84. PubMed ID: 26134219
[TBL] [Abstract][Full Text] [Related]
14. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I
PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172
[TBL] [Abstract][Full Text] [Related]
15. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis.
Hiraoka N; Yamazaki-Itoh R; Ino Y; Mizuguchi Y; Yamada T; Hirohashi S; Kanai Y
Gastroenterology; 2011 Jan; 140(1):310-21. PubMed ID: 20955708
[TBL] [Abstract][Full Text] [Related]
16. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A; Van Cutsem E
Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell immunotherapy induces antitumour response in parathyroid carcinoma and neuroendocrine pancreas carcinoma.
Schott M; Seissler J; Feldkamp J; von Schilling C; Scherbaum WA
Horm Metab Res; 1999 Dec; 31(12):662-4. PubMed ID: 10668919
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
19. Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.
Rice SJ; Miller B; Wagman M; Jamorabo DS; Liu X; Belani CP
Curr Mol Pharmacol; 2016; 9(3):183-195. PubMed ID: 26177648
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.
Mayor M; Yang N; Sterman D; Jones DR; Adusumilli PS
Eur J Cardiothorac Surg; 2016 May; 49(5):1324-33. PubMed ID: 26516195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
